WASHINGTON, D.C.: Allergan and Gedeon Richter have finally secured approval for Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults.
The drug is a potent dopamine D3/D2 receptor partial agonist atypical antipsychotic.
Clearance was based on a package of clinical data garnered from more than 2,700 adults, showing that Vraylar improved symptoms of both schizophrenia and bipolar disorder with an acceptable tolerability profile. Data also showed a 55% reduction in risk of relapse of schizophrenia versus placebo.